Recombinant VZV (strain Oka vaccine) Envelope Glycoprotein E

Specification

• Cat#: THP-0578
• Product Name: Recombinant VZV (strain Oka vaccine) Envelope Glycoprotein E
• Description: Recombinant VZV (strain Oka vaccine) Envelope Glycoprotein E is produced by a Mammalian expression system. The target gene encoding Ser31-Tyr538 is expressed with a C-terminal 6His tag.
• Molecular Weight: 58.4 kDa
• Introduction: Herpes zoster, commonly known as shingles, manifests as a painful, blistering rash resulting from the reactivation of latent varicella-zoster virus (VZV), primarily affecting the elderly and immunocompromised. A recombinant glycoprotein E (gE) subunit vaccine, formulated with the AS01B adjuvant, addresses the need for improved prevention. gE is the most abundant VZV glycoprotein on infected cells and elicits strong neutralizing antibody and CD4 T-cell responses. Essential for viral replication, gE mutations compatible with in vitro growth show distinct phenotypes in SCID mouse models of VZV pathogenesis.
• Purity: Purity exceeds 95% as assessed by reducing SDS-PAGE (QC verified).
• Storage: Upon reconstitution, store samples at -20°C or lower. The product remains stable for a minimum of 24 months under recommended storage conditions.
• Shipping Conditions: Transported using dry ice packs. Immediate storage at the specified temperature is required upon receipt.
• Formulation: Provided as a 0.2 μm filtered solution in PBS, pH 7.4.
• Size: 50μg/500μg/1g